布地奈德联合孟鲁司特纳对喘息性肺炎患儿免疫球蛋白及降钙素原的影响

Effects of budesonide combined with montelukast sodium on immunoglobulin and procalcitonin in children with asthmatic pneumonia

目的探讨布地奈德联合孟鲁司特纳在喘息性肺炎患儿中的临床效果及其对免疫球蛋白、降钙素原(procalcitonin,PCT)水平的影响。方法选择2017年11月至2018年12月来院治疗的喘息性肺炎患儿76例,随机分为对照组(n=38)和观察组(n=38)。两组均给予支持治疗,对照组联合布地奈德雾化治疗,观察组在对照组基础上联合孟鲁司特纳治疗,7 d后对患儿病情进行评估,比较两组治疗后免疫球蛋白、PCT水平及药物安全性等临床疗效。结果治疗后,观察组总有效率、免疫球蛋白水平高于对照组(P <0.05);治疗后7 d,观察组PCT水平低于对照组(P <0.05);治疗后观察组与对照组均有患儿出现排尿困难、咳嗽口干及呕吐等不良反应,但差异无统计学意义(P> 0.05)。结论布地奈德联合孟鲁司特纳用于喘息性肺炎患儿能提高患儿免疫球蛋白水平,降低PCT水平,且安全性良好,值得临床推广应用。

Objective To investigate the clinical effects of budesonide combined with montelukast sodium on immunoglobulin and procalcitonin in children with asthmatic pneumonia.Methods Seventy-six children with asthmatic pneumonia treated from November 2017 to December 2018 were enrolled.The children were randomly divided into control group(n=38)and observation group(n=38).Both groups were given supportive treatment.The control group was treated with budesonide atomization,the observation group was treated with montelukast sodium which on the basis of the control group.The effects of treatment in children were evaluated after 7 days.The immunoglobulin,procalcitonin levels,clinical efficacy and drug safety of the two groups after treatment were compared.Results After treatment,the total response rate and the levels of immunoglobulin in the observation group were higher than that in the control group(P<0.05).The procalcitonin level in the observation group was lower than that in the control group at 7 days after treatment(P<0.05).The incidence of dysuria,cough,dry mouth and vomiting after treatment in the observation group and the control group were not statistically significant(P>0.05).Conclusion Budesonide combined with montelukast sodium can increase the level of immunoglobulin in children with asthmatic pneumonia,decrease the procalcitonin level,and has high drug safety.It is worthy of popularization and application.